Dawnrays Pharmaceutical (Holdings) Limited EBIT

The latest EBIT for 2348.HK is $400M as of June 2026. That compares with $620M in the prior-year period — down 34.9% year over year. That is below the sector sector average of $2.6T. Investors often review this figure alongside Dawnrays Pharmaceutical (Holdings) Limited's historical trend and sector peers before judging valuation or financial health.

Over the past year, 2348.HK's EBIT moved from $620M to $400M — a 34.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Dawnrays Pharmaceutical (Holdings) Limited's operating scale or balance-sheet position.

Against its sector companies, 2348.HK currently prints $400M for EBIT, while the sector average sits near $2.6T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Dawnrays Pharmaceutical (Holdings) Limited's growth, margins, and balance sheet.

A EBIT figure of $400M for 2348.HK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.6T. Explore the charts below for those layers of context.

After noting 2348.HK's EBIT ($400M), review year-over-year change from $620M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.